TriSalus Life Sciences Launches PREDICTT Trial
WESTMINSTER, Colo. – May 4, 2026 TriSalus Life Sciences has announced the initiation of patient enrollment for its PREDICTT...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WESTMINSTER, Colo. – May 4, 2026 TriSalus Life Sciences has announced the initiation of patient enrollment for its PREDICTT...
DENVER, USA – March 18, 2026 TriSalus Life Sciences has announced new preclinical findings demonstrating that its Pressure-Enabled Drug...
